Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
16 hedge funds and large institutions have $1.03M invested in Statera Biopharma, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
7% more funds holding
Funds holding: 15 → 16 (+1)
18% less capital invested
Capital invested by funds: $1.26M → $1.03M (-$230K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$27.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.85K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.47K |
| 4 |
BlackRock
New York
|
+$1.24K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$328 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$38K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $567K | +$27.5K | +12,800 | +5% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $342K | – | – | – |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $55K | +$2.85K | +1,328 | +5% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $33K | – | – | – |
|
|
5
BlackRock
New York
| $30K | +$1.24K | +576 | +4% |
|
|
6
UBS Group
Zurich,
Switzerland
| $4K | +$1.47K | +686 | +50% |
|
|
7
Bank of America
Charlotte,
North Carolina
| $1K | +$328 | +153 | +153% |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$38K | -15,389 | Closed |
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$24 | +11 | New |
|
|
SWP
10
Stratos Wealth Partners
Beachwood,
Ohio
| – | +$215 | +100 | New |
|
STAB Hedge Fund Activity: Q3 2018 in Review
16 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2018, worth a combined $1.03M — down 18% from $1.26M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new STAB positions and 1 closed out — a net gain of 1 holder — while 5 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $27.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $38K sold.
- 16 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2018, up from 15 in Q2 2018.
- Funds reported $1.03M of Statera Biopharma, Inc. Common Stock stock for Q3 2018, down 18% quarter-over-quarter.
- 2 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2018 and 1 closed out, a net change of +1 holder.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q3 2018 was Renaissance Technologies, an estimated $27.5K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q3 2018 was Citadel Advisors, an estimated $38K sold.
Based on aggregated 13F filings for Q3 2018.